Seminars in Oncology
Volume 36, Issue 5 , Pages 375-379 , October 2009

Completely Regressed Cutaneous Melanocytic Lesion: Was It Benign or Was It Malignant?

References 

  1. Giuliano AE, Moseley HS, Morton DL. Clinical aspects of unknown primary melanoma. Ann Surg. 1980;191:98–104
  2. Chang P, Knapper WH. Metastatic melanoma of unknown primary. Cancer. 1982;49:1106–1111
  3. Reintgen DS, McCarty KS, Woodard B, Cox E, Seigler HF. Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet. 1983;156:335–340
  4. Bodurtha AJ. Spontaneous regression of malignant melanoma. In:  Clark WH,  Goldman LI,  Mastrangelo MJ editor. Human malignant melanoma. Orlando, FL: Grune & Stratton; 1978;p. 277–342
  5. Elder DE, Elenitsas R, Murphy GF, Xu X. Benign pigmented lesions and melanoma. In:  Elder DE editors. Lever's histopathology of the skin. 9th ed.. Philadelphia: Lippincott Williams & Wilkins; 2005;p. 447–449
  6. Zabawski EJ, Cockerell CJ. Halo nevus. Emedicine.medscape.com/article/1057446-overview
  7. Schmoeckel C, Wildi G, Schafer T. Spitz nevus versus malignant melanoma: Spitz nevi predominate on the thighs in patients younger than 40 years of age, melanomas on the trunk in patients forty years of age or older. J Am Acad Dermatol. 2007;56:753–758
  8. Pol-Rodriquez M, Lee S, Silvers DN, Celebi JT. Influence of age on survival in childhood Spitzoid melanomas. Cancer. 2007;109:1579–1583
  9. Busam KJ, Pulitzer M. Sentinel lymph node biopsy for patients with diagnostically controversial Spitzoid melanocytic tumors?. Adv Anat Pathol. 2008;15:253–262
  10. Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival after lymphadenectomy for nodal metastases from an unknown primary melanoma. J Clin Oncol. 2008;26:535–541
  11. Morton DL, Thompson JF, Cochran AJ, Mozzillo M, Elashoff R, Essner R, et al. Sentinel node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317
  12. McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with thin melanoma: influence of regression. Histopathology. 1983;7:673–680
  13. Wanebo HJ, Cooper PH, Hagar RW. Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression. Ann Surg. 1985;201:499–504
  14. Clark WH, Elder D, Guerry DuPont IV, Braitman LE, Rock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893–1904
  15. Paladuga RR, Yonemoto RH. Biological behavior of thin malignant melanomas with regressive changes. Arch Surg. 1983;118:41–44
  16. Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987;123:1326–1330
  17. Byers HR, Bhawan J. Pathologic parameters in the diagnosis and prognosis of primary cutaneous melanoma. Hematol Oncol Clin North Am. 1988;12:717–735
  18. Balch CM, Lange JR. Lymphatic mapping and sentinel node lymphadenectomy for cancer: an overview. Ann Surg Oncol. 2001;8(Suppl):1S–4S
  19. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995;274:1703–1705
  20. Poo-Hwu W-J, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, et al. Follow-up recommendations for patients with American Joint Committee on Cancer stages I-III malignant melanoma. Cancer. 1999;86:2252–2258

PII: S0093-7754(09)00145-6

doi: 10.1053/j.seminoncol.2009.07.010

Seminars in Oncology
Volume 36, Issue 5 , Pages 375-379 , October 2009

Article Tools

* Image Usage & Resolution